INTS
Intensity Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Strong sell
-64/100
Last price
3.55
▲ 0.10 (2.90%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
3.45
Day high
3.67
Day low
3.49
Volume
7.45K
Market cap
$11.59M
P/E (TTM)
—
52W range
3.21 – 43.50
Trailing performance
Returnvs SPY
1W
+3.80%
+1.9%
1M
-13.41%
-14.6%
3M
-27.55%
-32.1%
6M
-32.38%
-50.6%
YTD
-65.37%
-79.6%
1Y
-49.29%
-65.7%
3Y
-96.42%
-178.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
10 more panels on INTS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
127.89K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 30, 26 | TALAMO JOSEPH CPA Chief Financial Officer |
STOCK | 1.09K | $3.81K | Direct |
| Jun 30, 26 | WESOLOWSKI JOHN M CPA Officer |
STOCK | 3.69K | $12.85K | Direct |
| Mar 26, 26 | BENDER LEWIS H Chief Executive Officer |
STOCK | 37.75K | $230.65K | Direct |
| Dec 31, 25 | TALAMO JOSEPH CPA Chief Financial Officer |
STOCK | 14.48K | $3.79K | Direct |
| Dec 31, 25 | WESOLOWSKI JOHN M CPA Officer |
STOCK | 8.92K | $2.34K | Direct |
| Jun 30, 25 | TALAMO JOSEPH CPA Chief Financial Officer |
STOCK | 14.18K | $3.70K | Direct |
| Jun 30, 25 | WESOLOWSKI JOHN M CPA Officer |
STOCK | 69.75K | $18.20K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BENDER LEWIS H |
Chief Executive Officer | 118.55K | Stock Award(Grant) |
TALAMO JOSEPH CPA |
Chief Financial Officer | 2.24K | Stock Award(Grant) |
WESOLOWSKI JOHN M CPA |
Officer | 7.10K | Stock Award(Grant) |
Fundamentals
Market cap$11.59M
Enterprise value$2.16M
Revenue (TTM)—
Gross profit—
EBITDA—
Net income$-11.16M
EPS (TTM)$-3.89
Free cash flow$-6.28M
Total cash$9.53M
Total debt$95.00K
Book value / share$3.13
Shares outstanding3.26M
Float3.04M
Short % of float1.00%
Dividend yield0.00%
Beta (5Y)3.08
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.78
PEG ratio—
Price / sales—
Price / book1.13
EV / revenue—
EV / EBITDA—
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-195.88%
Return on assets-89.91%
Debt / equity1.03
Current ratio5.00
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $6.79M | $10.50M | $4.79M | $5.13M | -35.4% |
| Selling, general & admin | $5.19M | $6.09M | $3.53M | $2.42M | -14.8% |
| Total operating expense | $11.97M | $16.59M | $8.32M | $7.55M | -27.8% |
| Operating income | -$11.97M | -$16.59M | -$8.32M | -$7.55M | +27.8% |
| Net interest income | $180.00K | $314.00K | $19.00K | -$80.00K | -42.7% |
| Pre-tax income | -$11.61M | -$16.27M | -$10.54M | -$7.58M | +28.7% |
| Net income | -$11.61M | -$16.27M | -$10.54M | -$7.58M | +28.7% |
| Net income to common | -$11.61M | -$16.27M | -$11.86M | -$7.58M | +28.7% |
| Basic EPS | -8.56 | -29.24 | -34.50 | -54.73 | +70.7% |
| Diluted EPS | -8.56 | -29.24 | -34.50 | -54.73 | +70.7% |
| EBIT | -$11.97M | -$16.59M | -$10.23M | -$7.50M | +27.8% |
| EBITDA | -$11.97M | -$16.59M | -$10.23M | -$7.50M | +27.8% |
| Basic shares | 1.36M | 556.28K | 344.65K | 138.54K | +143.8% |
| Diluted shares | 1.36M | 556.28K | 344.65K | 523.98K | +143.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $11.92M | $2.59M | $8.56M | $1.31M | — | +360.3% |
| Cash & short-term investments | $11.92M | $2.59M | $14.78M | $1.31M | — | +360.3% |
| Total current assets | $12.71M | $3.36M | $15.46M | $1.45M | — | +277.9% |
| Property, plant & equipment | $96.00K | $122.00K | $147.00K | $139.00K | — | -21.3% |
| Total assets | $14.10M | $4.78M | $17.30M | $1.76M | — | +194.8% |
| Total current liabilities | $2.15M | $1.75M | $3.96M | $6.82M | — | +22.3% |
| Current debt | — | — | — | $4.35M | $2.02M | — |
| Total debt | $110.00K | $138.00K | $158.00K | $4.49M | — | -20.3% |
| Total liabilities | $2.23M | $1.86M | $4.13M | $16.86M | — | +19.3% |
| Retained earnings | -$78.39M | -$66.78M | -$50.52M | -$38.65M | — | -17.4% |
| Shareholder equity | $11.88M | $2.92M | $13.16M | -$15.10M | — | +307.0% |
| Working capital | $10.56M | $1.61M | $11.51M | -$5.37M | — | +556.9% |
| Net tangible assets | $11.88M | $2.92M | $13.16M | -$15.10M | — | +307.0% |
| Shares issued | 2.52M | 604.91K | 548.38K | 523.98K | — | +317.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$11.61M | -$16.27M | -$10.54M | -$7.58M | +28.7% |
| Stock-based compensation | $2.00M | $3.07M | $1.40M | $1.17M | -34.9% |
| Change in working capital | $347.00K | -$1.97M | -$436.00K | $757.00K | +117.6% |
| Operating cash flow | -$9.23M | -$15.22M | -$7.21M | -$5.48M | +39.3% |
| Investing cash flow | $0 | $6.35M | -$6.02M | $0 | -100.0% |
| Financing cash flow | $18.56M | $2.90M | $20.47M | $2.25M | +540.1% |
| Free cash flow | -$9.23M | -$15.22M | -$7.21M | -$5.48M | +39.3% |
| End cash position | $11.92M | $2.59M | $8.56M | $1.31M | +360.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $1.83M | $1.20M | $1.50M | $1.55M | $1.54M | — | +53.4% |
| Selling, general & admin | $1.25M | $1.33M | $1.64M | $1.18M | $1.16M | — | -6.0% |
| Total operating expense | $3.08M | $2.53M | $3.14M | $2.73M | $2.71M | — | +22.1% |
| Operating income | -$3.08M | -$2.53M | -$3.14M | -$2.73M | -$2.71M | — | -22.1% |
| Net interest income | $77.00K | $94.00K | $88.00K | $59.00K | $17.00K | — | -18.1% |
| Pre-tax income | -$3.01M | -$2.43M | -$3.05M | -$2.67M | -$2.54M | — | -23.5% |
| Net income | -$3.01M | -$2.43M | -$3.05M | -$2.67M | -$2.54M | — | -23.5% |
| Net income to common | -$3.01M | -$2.43M | -$3.05M | -$2.67M | -$2.54M | — | -23.5% |
| Basic EPS | -1.11 | -0.96 | — | -1.50 | -3.36 | -5.51 | -15.6% |
| Diluted EPS | -1.11 | -0.96 | — | -1.50 | -3.36 | -5.51 | -15.6% |
| EBIT | -$3.08M | -$2.53M | -$3.14M | -$2.73M | -$2.71M | — | -22.1% |
| EBITDA | -$3.08M | -$2.53M | -$3.14M | -$2.73M | -$2.71M | — | -22.1% |
| Basic shares | 2.71M | 2.53M | — | 1.72M | 754.73K | 606.93K | +6.8% |
| Diluted shares | 2.71M | 2.53M | — | 1.72M | 754.73K | 606.93K | +6.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $9.53M | $10.24M | $11.92M | $7.07M | $2.22M | -7.0% |
| Cash & short-term investments | $9.53M | $10.24M | $11.92M | $7.07M | $2.22M | -7.0% |
| Total current assets | $11.23M | $10.91M | $12.71M | $8.19M | $3.04M | +3.0% |
| Property, plant & equipment | $82.00K | $89.00K | $96.00K | $103.00K | $109.00K | -7.9% |
| Total assets | $11.52M | $12.29M | $14.10M | $9.59M | $4.44M | -6.3% |
| Total current liabilities | $2.25M | $2.24M | $2.15M | $2.28M | $2.16M | +0.1% |
| Total debt | $95.00K | $102.00K | $110.00K | $118.00K | $125.00K | -6.9% |
| Total liabilities | $2.31M | $2.31M | $2.23M | $2.36M | $2.26M | -0.2% |
| Retained earnings | -$83.83M | -$80.82M | -$78.39M | -$75.34M | -$72.67M | -3.7% |
| Shareholder equity | $9.21M | $9.98M | $11.88M | $7.22M | $2.18M | -7.7% |
| Working capital | $8.98M | $8.66M | $10.56M | $5.91M | $874.00K | +3.7% |
| Net tangible assets | $9.21M | $9.98M | $11.88M | $7.22M | $2.18M | -7.7% |
| Shares issued | 2.95M | 2.54M | 2.52M | 1.96M | 1.05M | +15.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$3.01M | -$2.43M | -$3.05M | -$2.67M | -$2.54M | — | -23.5% |
| Stock-based compensation | $387.00K | $387.00K | $450.00K | $471.00K | $644.00K | — | 0.0% |
| Change in working capital | $273.00K | $214.00K | $193.00K | -$193.00K | -$570.00K | — | +27.6% |
| Operating cash flow | -$2.34M | -$1.83M | -$2.40M | -$2.39M | -$2.46M | — | -28.1% |
| Investing cash flow | — | — | $0 | $0 | $0 | $0 | — |
| Financing cash flow | $1.62M | $150.00K | $7.25M | $7.24M | $3.74M | — | +982.7% |
| Free cash flow | -$2.34M | -$1.83M | -$2.40M | -$2.39M | -$2.46M | — | -28.1% |
| End cash position | $9.53M | $10.24M | $11.92M | $7.07M | $2.22M | — | -7.0% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.77 | -1.11 | -43.5% |
| Mar 2026 | -1.09 | -0.96 | +12.2% |
| Dec 2025 | -1.23 | — | — |
| Sep 2025 | -1.50 | -1.50 | 0.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.99 | 4 | $0 | 0.0% |
| Next quarter | -0.72 | 4 | $0 | 0.0% |
| Current year | -3.36 | 4 | $0 | 0.0% |
| Next year | -1.99 | 3 | $0 | 0.0% |
Analyst targets & ownership
Mean target$19.33
High target$32.00
Low target$7.00
Implied upside444.60%
Analyst count6
ConsensusNONE
Strong buy / Buy0 / 6
Hold0
Sell / Strong sell0 / 0
Held by insiders3.92%
Held by institutions36.55%
Institutions holding17
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
3.59
-1.06% from price
SMA 20
3.78
-6.06% from price
SMA 50
4.08
-12.90% from price
SMA 100
4.21
-15.58% from price
SMA 200
5.84
-39.16% from price
EMA 12
3.61
-1.62% from price
EMA 26
3.81
-6.84% from price
EMA 50
4.02
-11.64% from price
RSI (14)
40.6
Neutral
MACD (12,26,9)
-0.20
Hist -0.03
ATR (14)
0.29
8.09% of price
Realised vol 30D
53.5%
Annualised
Bollinger upper
4.32
20, 2σ
Bollinger lower
3.23
20, 2σ
50 / 200 cross
Death
4.08 vs 5.84
Trend bias
Below 200
-39.16%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-1.48
Less volatile than market
Correlation to SPY
-0.05
Largely independent
Realised vol 30D
53.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-90.3%
Peak to trough
Max drawdown 5Y
-98.7%
Peak to trough
ATR 14
0.29
8.09% of price
Beta (reported)
3.08
5Y monthly, from filing
Short interest
Shares short
31.30K
Prior 81.76K
Change vs prior
-61.7%
Shorts covering
% of float
1.00%
Normal
% of shares out
0.96%
Against total outstanding
Days to cover
1.1
Liquid
Float
3.04M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 20, 25 | Benchmark | MAINTAINED | Speculative Buy | Speculative Buy |
| Aug 12, 25 | Brookline Capital | UPGRADE | Hold | Buy |
| Jan 13, 25 | Alliance Global Partners | INITIATED | — | Buy |
| Nov 21, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 31, 24 | HC Wainwright & Co. | INITIATED | — | Buy |
| Jul 11, 24 | Benchmark | MAINTAINED | Speculative Buy | Speculative Buy |
| May 16, 24 | Benchmark | MAINTAINED | Speculative Buy | Speculative Buy |
| Mar 21, 24 | Benchmark | MAINTAINED | Speculative Buy | Speculative Buy |
| Nov 14, 23 | Benchmark | MAINTAINED | Speculative Buy | Speculative Buy |
| Aug 24, 23 | Benchmark | MAINTAINED | Speculative Buy | Speculative Buy |
| Jul 18, 23 | Benchmark | INITIATED | — | Speculative Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:25
Split dateFeb 19, 2026
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-11
Offering Registrations
S-8 · 2026-07-08
Corporate Changes & Voting Matters
8-K · 2026-06-16
Periodic Financial Reports
10-Q · 2026-05-07
Proxy Statements
DEF 14A · 2026-04-30
Periodic Financial Reports
10-K · 2026-03-27
Corporate Changes & Voting Matters
8-K · 2026-03-06
Corporate Changes & Voting Matters
8-K · 2026-03-05
Headlines
Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
PR Newswire · 29d ago
Intensity Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby · 56d ago
Intensity Therapeutics (INTS) Q2 2026 Earnings Call Transcript
Motley Fool · 56d ago
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
PR Newswire · 57d ago
Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
PR Newswire · 64d ago
Soft Tissue Sarcoma Market Set for Significant Growth at a CAGR of 7.9% During the Forecast Period (2026-2036), Driven by Novel Therapies and Expanding Treatment Landscape | DelveInsight
PR Newswire · 84d ago
Intensity Therapeutics Resumes Dosing in Phase 2 Trial for Investigational Cancer Therapy in Switzerland
MT Newswires · 84d ago
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
PR Newswire · 84d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.